FOLH1 and posterior cortical atrophy: Thirty nonmetastatic PCa patients treated by ADT and referred for PSMA-11 PET/CT between June 2016 and November 2018 because of a rise in PSA despite a suitable castrate serum level of testosterone were retrospectively included in this study (Table 1).